Dawn brings decades of experience to her role at AVROBIO, where she leads a team responsible for supply chain, external manufacturing, analytical sciences and technology and apheresis operations.

Prior to AVROBIO, she led Operations and Project Management at Lentigen Technology, Inc. for five years. Lentigen Technology, Inc is a CDMO specializing in cGMP manufacturing of lentiviral vector for cell and gene therapy. During her time, she built the Project Management team responsible for interacting with clients and directing internal deliverables to meet contractual requirements. She worked cross functionally to develop the serum free suspension platform process for lentiviral vector manufacturing that leads the field today. Previously, she worked at the Southern Research Institute for 11 years in a variety of scientific roles and ultimately led a team responsible for analytical development, qualification, and validation of assays to support GLP preclinical studies for infectious disease therapies and vaccines. Additionally, she was responsible for site data management and project coordination to support both government and commercial client contracts.

Early in her career, she worked at the bench at Genetic Therapy, Inc., a Novartis Company, driving forward various vector platform technologies impacting gene therapy programs for hemophilia A and B, oncology indications as well as ocular disease.

Dawn graduated from the Florida Institute of Technology with a B.S. in Molecular Biology.